{ "vercy": "1.0-draft", "publication": { "status": "research-draft", "adjudicationStatus": "unreviewed", "publishableCanonical": false, "generatedAt": "2026-09-12T10:39:14Z", "providers": [ "Codex" ], "breadth": "recalled by Codex without web access - no source was read", "missingProviders": [], "pass": 2, "cost": { "grok": { "seconds": 18.0, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09532-029e-73e3-9efc-08ff26ca1883\n--------\nuser\nDescribe what is already known about one registered thing. Answer as JSON only, no prose around it.\n\nThing: ixazomib\nSense to describe: (none recorded)\nDomain code: PHY.MAT\nAlso known as: (none)\n\n\nContext for this batch of 1001 things:\n# Batch 043: 1001 regist", "usd": 0.0, "recall": true }, "codex": { "seconds": 77.5, "error": "Reading additional input from stdin...\nOpenAI Codex v0.153.4\n--------\nworkdir: R:\\02_PROJECTS\\02_Meta_Models_Platforms\\Ver.cy\\current\\thing-registry-backlog\nmodel: gpt-6-astra\nprovider: openai\napproval: never\nsandbox: read-only\nreasoning effort: none\nreasoning summaries: none\nsession id: 01a09532-02ac-78c2-af89-9fc930dab4f0\n--------\nuser\nYou are drafting a Vercy meta-model for one registered thing. Answer as JSON only, no prose around it.\n\nThing: ixazomib\nRegistry id: vr.tr.ixazomib\nPlane / domain: PHY / PHY.MAT\nRegistry definition: (none recorded)\nNames folded into this entry: (none)\n\n\nContex" } }, "enrichment": { "pass": 3, "engine": "claude", "producedAt": "2026-10-06T12:00:00Z", "ingestedAt": "2026-10-06T08:53:40+00:00", "fields": [ "agent_conduct", "ethics", "failure_modes_and_hazards", "owners", "visual_identification" ] }, "gate": { "passed": true, "version": "1.0", "at": "2026-10-07T10:10:28+00:00", "evidence": [ "completeness 1.00", "sense: Wikidata description", "2 live sources", "review by codex: pass" ] } }, "metaModel": { "id": "THING-Q20948663", "registryId": "vr.tr.ixazomib", "name": "ixazomib", "version": "0.1.0-research.1", "entryKind": "thing", "family": "Thing Registry", "domain": [ "PHY.MAT" ], "status": "research-draft" }, "canonicalUrl": "https://ver.cy/models/thing/q20948663/", "model": { "registry_id": "vr.tr.ixazomib", "name": "ixazomib", "purpose": "Enable an AI agent to recognize ixazomib, assess the identity and condition of a material containing it, and determine whether evidence supports a proposed analytical, research, or handling action.", "definition": "Ixazomib is a small-molecule boronic acid proteasome inhibitor used in combination therapy for multiple myeloma and administered orally as the citrate ester prodrug ixazomib citrate.", "scope_statement": "This model owns the chemical-substance identity and material-state assessment of ixazomib under vr.tr.ixazomib in PHY / PHY.MAT, including its relationship to its citrate prodrug, without treating the prodrug or finished medicine as the same material.", "in_scope": [ "Chemical structure, stereochemical identity, identifiers, and verified synonyms of ixazomib.", "Distinction between ixazomib, ixazomib citrate, and quantities expressed as ixazomib equivalents.", "Sample composition, purity, impurities, concentration, and analytical evidence.", "Physical state, solution conditions, stability, and storage history of identified ixazomib material.", "Proteasome-inhibition evidence and substance-specific handling constraints." ], "out_of_scope": [ "Independent characterization and manufacture of ixazomib citrate.", "NINLARO capsule formulation, packaging, and finished-product release specifications.", "Patient-specific prescribing, dosing, treatment selection, and adverse-event management.", "Multiple myeloma biology and treatment-regimen models.", "Manufacturing equipment, synthesis workflows, and institutional laboratory-safety systems." ], "distinguishing_features": [ "Check which chemical species is present: the FDA label distinguishes biologically active ixazomib from ixazomib citrate, a prodrug that hydrolyzes to it. [FDA NINLARO label, section 11](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208462s016lbl.pdf)", "Require a structure and stereochemical match; a shared proteasome-inhibitor designation does not establish identity as ixazomib.", "Distinguish measured substance mass from ixazomib-equivalent mass: the label reports capsule contents using different masses for ixazomib and ixazomib citrate. [FDA NINLARO label, section 11](https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/208462s016lbl.pdf)", "Determine whether the record describes an isolated substance, a solution, or a formulated capsule before assigning purity, physical properties, or handling requirements." ], "characteristics": [ { "name": "Chemical and stereochemical identity", "kind": "category", "unit_or_values": "Verified structure with explicit stereochemistry; identity confirmed, provisional, or unresolved", "why_it_matters": "Prevents citrate-prodrug records and structurally related inhibitors from being assigned to ixazomib." }, { "name": "Identifier correspondence", "kind": "relation", "unit_or_values": "CAS, PubChem CID, UNII, and EC identifier where available, each linked to an exact structure and source", "why_it_matters": "A familiar name alone cannot establish that external records describe the same chemical species." }, { "name": "Material composition", "kind": "category", "unit_or_values": "Isolated ixazomib, mixture, solution, or unresolved composition; components and grade recorded", "why_it_matters": "Determines whether substance properties and intended-use requirements apply to the actual sample." }, { "name": "Ixazomib content", "kind": "measurement", "unit_or_values": "Mass fraction %, mg/g, mg/mL, or mol/L with analytical method and reporting basis", "why_it_matters": "Supports valid preparation and comparison without confusing actual ixazomib content with prodrug-equivalent quantities." }, { "name": "Stereochemical purity", "kind": "measurement", "unit_or_values": "Enantiomeric ratio or enantiomeric excess %, with method and detection limits", "why_it_matters": "Chemical purity alone may not establish conformity to the intended stereochemical identity." }, { "name": "Impurity profile", "kind": "measurement", "unit_or_values": "Individual and total impurities in %, ppm, or mass concentration, with identified and unidentified fractions", "why_it_matters": "Separates nominal identity from suitability for a particular analytical or research use." }, { "name": "Physical and solution state", "kind": "state", "unit_or_values": "Solid or solution; phase characterization, solvent, pH, temperature in °C, and elapsed preparation time", "why_it_matters": "Conditions determine whether measurements concern the same material state." }, { "name": "Proteasome-inhibition measurement", "kind": "measurement", "unit_or_values": "IC50 or other defined endpoint in nM or µM, with target preparation, substrate, incubation time, and controls", "why_it_matters": "Makes biological-activity evidence interpretable without using activity alone as an identity test." }, { "name": "Handling evidence status", "kind": "state", "unit_or_values": "Verified, incomplete, conflicting, or unavailable; linked to material-specific SDS and applicable jurisdiction", "why_it_matters": "Prevents unsupported transfer of product warnings or another chemical form's classification." } ], "affordances": [ "Resolve an ixazomib-labelled record against structure-specific identifiers and flag citrate-prodrug or product ambiguity.", "Assess a lot against documented identity, purity, stereochemistry, and intended-use criteria.", "Normalize quantities only after verifying chemical species, molecular-mass basis, and assay correction.", "Compare solubility, stability, and activity measurements under explicitly matched experimental conditions.", "Identify whether storage, handling, or disposal evidence supports a proposed action and flag unresolved requirements." ], "agent_conduct": { "may": [ "Explain ixazomib as an oral proteasome inhibitor for multiple myeloma, citing official labelling.", "Report indications, contraindications and warnings from the medicine's label." ], "must_not": [ "Recommend, dose or adjust ixazomib for a specific person.", "Advise obtaining cancer medicines without a prescription or from unverified sellers.", "Present it as a cure or as effective outside its approved uses without evidence.", "Handle cytotoxic medicines without the precautions their label requires." ], "requires_human": [ "Starting, stopping or changing cancer treatment for a patient." ] }, "ethics": { "considerations": [ "Patients with cancer are vulnerable to false hope and counterfeit drugs.", "Access to costly cancer medicines raises fairness questions." ], "affected_parties": [ "Patients with myeloma", "Carers", "Prescribers and pharmacists" ] }, "owners": { "steward": "The prescriber and the pharmacist for each patient; medicines regulators authorize products.", "master_systems": [ "National medicines registers" ] }, "visual_identification": [ "Identified by product label, active ingredient name and pack details rather than by appearance alone." ], "failure_modes_and_hazards": [ "Low platelet counts and bleeding.", "Peripheral nerve damage.", "Counterfeit or diverted cancer drugs." ], "what_it_is_for": [ "Ixazomib is encountered in pharmaceutical research, analytical laboratories and oncology medicines supplied through its citrate prodrug.", "Its clinical context is combination treatment for multiple myeloma, while laboratory work may examine identity, purity, stability or proteasome inhibition." ], "standards_and_regulation": [ "The Anatomical Therapeutic Chemical classification maintained by the World Health Organization Collaborating Centre for Drug Statistics Methodology assigns ixazomib code L01XG03 within proteasome inhibitors." ] }, "sources": [ { "id": "wikidata", "title": "Wikidata item Q20948663: ixazomib", "url": "https://www.wikidata.org/wiki/Q20948663", "url_status": "live", "what_it_supports": "identity and sense of the item", "checked_by": "wikidata-api" }, { "id": "wikipedia-en", "title": "Wikipedia: Ixazomib", "url": "https://en.wikipedia.org/wiki/Ixazomib", "url_status": "live", "what_it_supports": "general description of the item", "checked_by": "wikidata-api sitelink" } ], "structure": { "bundles": [ { "id": "ixazomib-identity", "name": "Ixazomib identity", "description": "Establish which chemical entity the registry entry and a candidate material describe.", "rationale": "Ixazomib naming can appear alongside citrate-prodrug and medicinal-product records, making name matching insufficient.", "layers": [ { "id": "structure-and-stereochemistry", "name": "Structure and stereochemistry", "description": "Anchor identification to molecular connectivity and stereochemical specification.", "findings": [ { "id": "structure-identity-evidence", "name": "Structure identity evidence", "description": "Require an authoritative structure reference and sample evidence appropriate to the claimed identity.", "questions": [ { "text": "Which explicit molecular structure and stereochemical configuration define ixazomib for this entry?", "kind": "definition", "id": "structure-identity-evidence-q01" }, { "text": "Which analytical results establish that the sample matches this identity rather than a related compound or stereoisomer?", "kind": "measurement", "id": "structure-identity-evidence-q02" } ] } ] }, { "id": "names-and-entity-boundaries", "name": "Names and entity boundaries", "description": "Reconcile external identifiers while preserving substance, prodrug, and product distinctions.", "findings": [ { "id": "identifier-species-alignment", "name": "Identifier species alignment", "description": "Accept an identifier or synonym only when its referenced chemical entity has been checked.", "questions": [ { "text": "Which CAS, PubChem, UNII, and available EC records resolve specifically to ixazomib, and which resolve to ixazomib citrate?", "kind": "provenance", "id": "identifier-species-alignment-q01" }, { "text": "Does an incoming use of the name ixazomib denote the active substance, a prodrug-containing material, or a finished medicine?", "kind": "boundary", "id": "identifier-species-alignment-q02" } ] } ] } ] }, { "id": "composition-and-quantity", "name": "Composition and quantity", "description": "Establish what a sample contains and what its stated quantity means.", "rationale": "Purity, stereochemistry, and ixazomib-equivalent reporting affect whether material can be compared or used correctly.", "layers": [ { "id": "lot-quality", "name": "Lot quality", "description": "Assess chemical content, stereochemical purity, and impurities for the intended use.", "findings": [ { "id": "lot-conformity-evidence", "name": "Lot conformity evidence", "description": "Treat grade and purity claims as evidence-dependent properties of a specific lot.", "questions": [ { "text": "What methods quantify ixazomib content, stereochemical purity, residual solvents, and relevant impurities in this lot?", "kind": "measurement", "id": "lot-conformity-evidence-q01" }, { "text": "Which certificate, reference standard, and acceptance criteria support the claimed grade and intended use?", "kind": "provenance", "id": "lot-conformity-evidence-q02" } ] } ] }, { "id": "mass-and-concentration-basis", "name": "Mass and concentration basis", "description": "Keep chemical-species mass distinct from active-moiety equivalents and solution concentration.", "findings": [ { "id": "quantity-basis-validation", "name": "Quantity basis validation", "description": "Require explicit species, units, purity correction, and conversion assumptions before normalizing quantities.", "questions": [ { "text": "Is the reported amount actual ixazomib mass, ixazomib citrate mass, or an amount expressed as ixazomib equivalents?", "kind": "boundary", "id": "quantity-basis-validation-q01" }, { "text": "Which verified molecular masses, assay values, and solution volumes justify the proposed conversion or preparation?", "kind": "action", "id": "quantity-basis-validation-q02" } ] } ] } ] }, { "id": "physical-state-and-transformation", "name": "Physical state and transformation", "description": "Describe ixazomib material under defined conditions and track changes in its composition.", "rationale": "Properties of the citrate prodrug or formulated capsule cannot automatically characterize isolated ixazomib.", "layers": [ { "id": "conditioned-physical-properties", "name": "Conditioned physical properties", "description": "Associate physical measurements with the tested chemical form and experimental conditions.", "findings": [ { "id": "form-specific-property-evidence", "name": "Form-specific property evidence", "description": "Record phase, solubility, and thermal behavior only with enough context to identify what was measured.", "questions": [ { "text": "Which phase, solvent, pH, temperature, and analytical method accompany a reported ixazomib solubility or physical constant?", "kind": "measurement", "id": "form-specific-property-evidence-q01" }, { "text": "Does each reported melting, boiling, or decomposition observation concern ixazomib itself, and is the stated endpoint physically applicable?", "kind": "boundary", "id": "form-specific-property-evidence-q02" } ] } ] }, { "id": "species-change-and-stability", "name": "Species change and stability", "description": "Distinguish generation of ixazomib from its subsequent persistence or degradation.", "findings": [ { "id": "time-dependent-composition", "name": "Time-dependent composition", "description": "Track starting material, conversion evidence, and the composition present at the time of use.", "questions": [ { "text": "If a preparation starts from ixazomib citrate, what measurement establishes the ixazomib fraction at the time of analysis?", "kind": "measurement", "id": "time-dependent-composition-q01" }, { "text": "What data support the proposed storage duration, solvent conditions, and retest interval for this specific ixazomib material?", "kind": "action", "id": "time-dependent-composition-q02" } ] } ] } ] }, { "id": "proteasome-activity-evidence", "name": "Proteasome activity evidence", "description": "Represent experimentally supported biological activity and its interpretation limits.", "rationale": "Proteasome-inhibitor identity needs assay context; biochemical activity does not by itself establish sample identity or clinical suitability.", "layers": [ { "id": "target-assay-context", "name": "Target assay context", "description": "Make potency and inhibition observations comparable through explicit assay conditions.", "findings": [ { "id": "interpretable-inhibition-result", "name": "Interpretable inhibition result", "description": "Connect an inhibition endpoint to the tested species, target preparation, substrate, and timing.", "questions": [ { "text": "Which proteasome preparation, catalytic activity, substrate, incubation time, and endpoint were used to measure ixazomib inhibition?", "kind": "measurement", "id": "interpretable-inhibition-result-q01" }, { "text": "Was ixazomib tested directly, or was activity attributed to conversion from ixazomib citrate under the assay conditions?", "kind": "provenance", "id": "interpretable-inhibition-result-q02" } ] } ] }, { "id": "activity-interpretation", "name": "Activity interpretation", "description": "Separate chemical quality, biochemical inhibition, and cellular response.", "findings": [ { "id": "activity-transfer-limits", "name": "Activity transfer limits", "description": "Require evidence before transferring activity conclusions between lots, assays, or biological systems.", "questions": [ { "text": "Which controls distinguish proteasome inhibition from assay interference or nonspecific loss of cell viability?", "kind": "measurement", "id": "activity-transfer-limits-q01" }, { "text": "What additional evidence is required before using this activity result to accept a lot or select it for a different experiment?", "kind": "action", "id": "activity-transfer-limits-q02" } ] } ] } ] }, { "id": "handling-and-use-constraints", "name": "Handling and use constraints", "description": "Connect a proposed material action to relevant hazard, provenance, and regulatory evidence.", "rationale": "Substance handling decisions require evidence for the actual material rather than assumptions drawn from a medicine's therapeutic use.", "layers": [ { "id": "material-specific-hazards", "name": "Material-specific hazards", "description": "Assess exposure and disposal requirements for the identified ixazomib form and concentration.", "findings": [ { "id": "hazard-evidence-applicability", "name": "Hazard evidence applicability", "description": "Check that hazard classifications and controls apply to the material and planned operation.", "questions": [ { "text": "Which current SDS and jurisdiction-specific GHS classification apply to this ixazomib material rather than its citrate prodrug or finished capsules?", "kind": "provenance", "id": "hazard-evidence-applicability-q01" }, { "text": "What documented controls and waste route apply to weighing, dissolving, transferring, or disposing of this material?", "kind": "action", "id": "hazard-evidence-applicability-q02" } ] } ] }, { "id": "intended-use-eligibility", "name": "Intended-use eligibility", "description": "Relate material provenance and grade to the proposed use without making patient-treatment decisions.", "findings": [ { "id": "use-authorization-evidence", "name": "Use authorization evidence", "description": "Keep research-material qualification separate from approval of a finished medicinal product.", "questions": [ { "text": "What supplier, lot, custody history, and grade documentation support this material's intended analytical or research use?", "kind": "provenance", "id": "use-authorization-evidence-q01" }, { "text": "Which restrictions apply to the proposed use, and is any claimed medicinal authorization actually attached to a separate finished product?", "kind": "boundary", "id": "use-authorization-evidence-q02" } ] } ] } ] }, { "id": "evidence-and-external-alignment", "name": "Evidence and external alignment", "description": "What the world already says about this thing, gathered so the model can be checked against it.", "rationale": "A model that cannot be lined up against existing standards, identifiers and practice cannot be adopted by anyone who already uses them.", "layers": [ { "id": "reported-evidence", "name": "Reported evidence", "description": "Findings from the breadth pass, kept separate from the structural claims.", "findings": [ { "id": "evidence-confidence-notes", "name": "Check these first", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "This description is recalled knowledge, not a report of sources read.", "Verify chemical identifiers and physical constants against the active compound specifically; records for ixazomib citrate must not be substituted.", "Verify current jurisdiction-specific indications and prescribing information; the hazards listed concern medicinal exposure and do not establish a laboratory GHS classification." ], "questions": [ { "id": "evidence-confidence-notes-q01", "text": "Which of these check these first hold for the sense of ixazomib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-identifiers", "name": "Identifiers and schemes", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "scheme": "International Nonproprietary Name (INN)", "value_or_pattern": "ixazomib", "note": "Names the active compound; ixazomib citrate is its distinct prodrug form." }, { "scheme": "Drug development code", "value_or_pattern": "MLN2238", "note": "Identifies ixazomib; MLN9708 identifies ixazomib citrate." } ], "questions": [ { "id": "evidence-identifiers-q01", "text": "Which of these identifiers and schemes hold for the sense of ixazomib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-standards-and-regulation", "name": "Standards and regulation", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "United States Food and Drug Administration prescription-drug approval and prescribing-information requirements apply to medicinal products containing ixazomib citrate." ], "questions": [ { "id": "evidence-standards-and-regulation-q01", "text": "Which of these standards and regulation hold for the sense of ixazomib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-real-world-use", "name": "Real-world use", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Treatment of multiple myeloma in combination with lenalidomide and dexamethasone.", "Research on proteasome inhibition and its effects on malignant plasma cells." ], "questions": [ { "id": "evidence-real-world-use-q01", "text": "Which of these real-world use hold for the sense of ixazomib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-failure-modes-and-hazards", "name": "Failure modes and hazards", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ "Thrombocytopenia during treatment.", "Gastrointestinal adverse effects, including diarrhea, nausea and vomiting.", "Peripheral neuropathy.", "Rash.", "Embryo-fetal toxicity." ], "questions": [ { "id": "evidence-failure-modes-and-hazards-q01", "text": "Which of these failure modes and hazards hold for the sense of ixazomib this model covers, and on what evidence?", "kind": "provenance" } ] }, { "id": "evidence-neighbours", "name": "Neighbouring kinds and how to tell them apart", "description": "Recalled without web access and unsourced; every item is a lead to verify.", "evidence": [ { "name": "ixazomib citrate", "difference": "A citrate ester prodrug that hydrolyzes to ixazomib; it is a distinct chemical substance, not simply another name for the active compound." }, { "name": "Ninlaro", "difference": "A branded medicinal product containing ixazomib citrate, rather than the isolated active chemical substance." }, { "name": "bortezomib", "difference": "A chemically distinct boronic acid proteasome inhibitor administered by injection." }, { "name": "carfilzomib", "difference": "An epoxyketone proteasome inhibitor that binds irreversibly, whereas ixazomib inhibits reversibly." } ], "questions": [ { "id": "evidence-neighbours-q01", "text": "Which of these neighbouring kinds and how to tell them apart hold for the sense of ixazomib this model covers, and on what evidence?", "kind": "provenance" } ] } ] } ] } ] }, "openQuestions": [ "Which authoritative structure, stereochemical specification, CAS number, PubChem CID, UNII, and available EC identifier should anchor ixazomib independently of ixazomib citrate?", "Which measured physical constants, solid forms, and solvent-dependent solubilities are established for ixazomib itself, and which commonly cited values belong to the citrate prodrug?", "What validated methods and acceptance criteria distinguish ixazomib, residual citrate prodrug, stereochemical impurities, and degradation products in relevant materials?", "What stability data establish storage, solution lifetime, and conversion behavior under the conditions in which agents will encounter ixazomib?", "Which current material-specific hazard classifications, occupational exposure limits if established, and jurisdictional use restrictions apply to isolated ixazomib?" ], "statistics": { "bundles": 6, "layers": 11, "findings": 16, "questions": 26 } }